Koers Curative Biotechnology, Inc. Other OTC
Aandelen
CTYX
US20786Q2093
Biotechnologie & Medisch Onderzoek
Omzet 2020 | - | Omzet 2021 | - | Marktkapitalisatie | 29,41 mln. 27,58 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2020 | -4 mln. -3,75 mln. | Nettowinst (verlies) 2021 | -5 mln. -4,69 mln. | EV/omzet 2020 | - |
Nettoschuld 2020 | 399K 374K | Nettoliquiditeiten 2021 | 670K 629K | EV/omzet 2021 | - |
K/w-verhouding 2020 |
-2,11
x | K/w-verhouding 2021 |
-1,44
x | Werknemers | - |
Dividendrendement 2020 * |
-
| Dividendrendement 2021 |
-
| Vrij verhandelbaar | 99,95% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
I. Garr
CEO | Chief Executive Officer | 71 | 11-02-21 |
Paul M. Michael
CHM | Chairman | - | - |
Steve Chizzik
IRC | Investor Relations Contact | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Cary Sucoff
BRD | Director/Board Member | 71 | 12-05-22 |
Theresa Heah
BRD | Director/Board Member | 46 | 31/03 |
Lawrence Zaslow
BRD | Director/Board Member | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,86 mld. | |
+10,92% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,23% | 25,15 mld. | |
-24,79% | 18,63 mld. | |
+26,69% | 12,37 mld. | |
-3,13% | 11,92 mld. | |
+6,57% | 11,21 mld. |